WCG today announced its acquisition of Trifecta Clinical, a proven leader in technology-enabled clinical trial solutions, including its comprehensive site communication platform InvestigatorSpace®, virtual training programs and safety documentation services.
The acquisition of Trifecta expands the range of specialized services and solutions WCG offers and enhances the ability to connect sites, sponsors and CROs across the clinical trials ecosystem.
“With a host of services that fully integrate clinical trial training and communication, from safety letter notification to regulatory document exchange, Trifecta adds another dimension to WCG’s compelling value proposition,” said Donald A. Deieso, Ph.D., Executive Chairman and CEO of WCG. “This acquisition is part of our effort to pursue strategic opportunities that allow us to expand and enhance our offerings in anticipation of our customers’ needs. We’re pleased to be joining forces with an innovative company such as Trifecta and working together to help sponsors, CROs, and clinical research sites increase efficiency and the quality of the work they do every day.”
Dave Young, Trifecta’s Founder and CEO, added: “We’re thrilled to be joining WCG, a company that shares our passion for improving the clinical trial process by delivering impactful solutions to age-old problems. This acquisition was a natural evolution for Trifecta. Now as part of WCG, we can help our customers by continuing to provide perpetual innovation, rooted in unrivaled expertise.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Moving forward, Trifecta will be known as WCG Trifecta, and will retain its leadership structure, along with its headquarters in Los Angeles, and locations in Indianapolis, Philadelphia, and Osaka, Japan.
Source: Biospace